AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.

By GlobeNewswire

AYTU shareholders will receive just $2.70 per share in a tender offer transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers

CLICK HERE TO JOIN

MILWAUKEE, Nov. 17, 2026 (GLOBE NEWSWIRE) --

MILWAUKEE (GlobeNewswire) -- Ademi LLP is investigating whether the proposed acquisition of Aytu (NASDAQ: AYTU) by Rosemont Pharmaceuticals, provides fair value to Aytu’s public shareholders and whether Aytu’s Board adequately protected shareholder interests in negotiating and approving the transaction.

Are You a AYTU Shareholder?
If you own Aytu shares, Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.

You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995.
There is no cost or obligation to you.

What Is Ademi LLP Investigating?
The purchase price and whether it adequately reflects Aytu’s value and future prospects;

Substantial change-of-control benefits available to Aytu insiders in connection with the transaction;

Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and

The conduct of Aytu’s Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.

What Should AYTU Shareholders Do?
Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.

Guri Ademi
Ademi LLP
Toll Free: (866) 264-3995
Email: gademi@ademilaw.com

About Ademi LLP
Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Ademi LLP


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.